» Articles » PMID: 28864619

Therapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2017 Sep 3
PMID 28864619
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, new α-particle-, β-particle-, and Auger electron-emitting radiometals-such as Cu, Sc, Ho, Tb, Tb, Pb/Bi, Ac, and Bi-have been produced and evaluated (pre)clinically for therapeutic purposes. In this short review article, the most important routes of production of these radiometals are critically discussed, as are examples of their application in preclinical and clinical studies.

Citing Articles

Evaluation of a novel Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile.

Liu Y, Oroujeni M, Liao Y, Vorobyeva A, Bodenko V, Orlova A Eur J Nucl Med Mol Imaging. 2024; 51(13):4038-4048.

PMID: 39008065 PMC: 11527907. DOI: 10.1007/s00259-024-06840-5.


Engineered Antibodies as Cancer Radiotheranostics.

Wei Z, Li B, Wen X, Jakobsson V, Liu P, Chen X Adv Sci (Weinh). 2024; 11(30):e2402361.

PMID: 38874523 PMC: 11321656. DOI: 10.1002/advs.202402361.


First preclinical evaluation of [Ac]Ac-DOTA-JR11 and comparison with [Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.

Handula M, Beekman S, Konijnenberg M, Stuurman D, de Ridder C, Bruchertseifer F EJNMMI Radiopharm Chem. 2023; 8(1):13.

PMID: 37389800 PMC: 10313624. DOI: 10.1186/s41181-023-00197-0.


Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.

Chakraborty K, Mondal J, An J, Park J, Lee Y Pharmaceutics. 2023; 15(3).

PMID: 36986832 PMC: 10054444. DOI: 10.3390/pharmaceutics15030971.


Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.

Anderson P, Subbiah V, Trucco M Front Med (Lausanne). 2022; 9:1030094.

PMID: 36457575 PMC: 9705365. DOI: 10.3389/fmed.2022.1030094.